A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback